Given the observation that Namodenoson downregulates a broad range of HDAC enzymes in tumor cells, we hypothesized that a combination of ADORA3 activation and inhibition of HDACs might be able to enhance the therapeutic efficacy of either treatment alone. This evidence concerns the gene ADORA3 and neoplasm.